Abstract:The RAS–RAF–MEK–ERK pathway is the most well-studied of the MAPK cascades and is critical for cell proliferation, differentiation, and survival. Abnormalities in regulation resulting from mutations in components of this pathway, particularly in upstream proteins, RAS and RAF, are responsible for a significant fraction of human cancers and nearly all cutaneous melanomas. Activation of receptor tyrosine kinases by growth factors and various extracellular signals leads to the sequential activation of RAS, RAF, MEK, and finally ERK, which activates numerous transcription factors and facilitates oncogenesis in the case of aberrant pathway activation. While extensive studies have worked to elucidate the activation mechanisms and structural components of upstream MAPK components, comparatively less attention has been directed toward the kinases, MEK and ERK, due to the infrequency of oncogenic-activating mutations in these kinases. However, acquired drug resistance has become a major issue in the treatment of RAS- and RAF-mutated cancers. Targeting the terminal kinases in the MAPK cascade has shown promise for overcoming many of these resistance mechanisms and improving treatment options for patients with MAPK-aberrant cancers. Here, we will describe the role of MEK and ERK in MAPK signaling and summarize the current understanding of their interaction and activation mechanisms. We will also discuss existing approaches for targeting MEK and ERK, and the benefits of alternative strategies. Areas requiring further exploration will be highlighted to guide future research endeavors and aid in the development of alternative therapeutic strategies to combat surmounting drug resistance in treating MAPK-mediated cancers. Visual Overview: http://mcr.aacrjournals.org/content/molcanres/19/3/361/F1.large.jpg .

Progress in the development of ERK1/2 inhibitors for treating cancer and other diseases

Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy

Targeting Extracellular Signal-Regulated Protein Kinase 1/2 (ERK1/2) in Cancer: an Update on Pharmacological Small-Molecule Inhibitors.

ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

Targeting the ERK signaling pathway in cancer therapy

Developments in Mitogen-Induced Extracellular Kinase 1 Inhibitors and Their Use in the Treatment of Disease

ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

AKT and ERK dual inhibitors: The way forward?

ERK: A Double-Edged Sword in Cancer. ERK-Dependent Apoptosis as a Potential Therapeutic Strategy for Cancer

Targeting the RAF–MEK–ERK pathway in cancer therapy

Synergistic Anticancer Effect by Targeting CDK2 and EGFR-ERK Signaling.

Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy

Targeting RAS–ERK signalling in cancer: promises and challenges

ERK signalling: a master regulator of cell behaviour, life and fate

The Overview of Mitogen-activated Extracellular Signal-Regulated Kinase (Mek)-Based Dual Inhibitor in the Treatment of Cancers.

The MEK/ERK Network as a Therapeutic Target in Human Cancer

Targeting RAS-RAF-MEK-ERK Signaling Pathway in Human Cancer: Current Status in Clinical Trials.

Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy

Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma